Advertisement
| car t vs tcr therapy: Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book Daniel W. Lee, Nirali N. Shah, 2019-11-30 From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. - Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. - Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. - Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. - Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy. |
| car t vs tcr therapy: The EBMT/EHA CAR-T Cell Handbook Nicolaus Kröger, John Gribben, Christian Chabannon, Ibrahim Yakoub-Agha, Hermann Einsele, 2022-02-07 This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers’ knowledge and practice skills. |
| car t vs tcr therapy: Interaction of Immune and Cancer Cells Magdalena Klink, Izabela Szulc-Kielbik, 2022-02-14 Now, it its second edition, this book summarizes the role of immune cells in tumor suppression and progression. It describes in detail why tumor cells can survive and spread in spite of the antitumor response of immune cells. Since immunotherapy is an attractive approach to cancer therapy, this book also provides information on the two main strategies: monoclonal antibodies and adaptive T cell immunotherapy, with a focus on recent human clinical trials. A newly added chapter also focuses on the role of Natural Killer cells in tumor progression. The book provides a state-of-the-art, comprehensive overview of immune cells in cancer and is an indispensable resource for researchers and practitioners working or lecturing in the field of cancer research and immunology. |
| car t vs tcr therapy: Gene and Cellular Immunotherapy for Cancer Armin Ghobadi, John F. DiPersio, 2022-01-01 Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia (ALL). These advances have dramatically improved the management of patients with relapsed refractory lymphoma, myeloma and leukemia. Gene and Cellular Immunotherapy for Cancer offers readers a comprehensive review of current cellular and gene-based immunotherapies. Divided into eighteen cohesive chapters, this book provides an in-depth and detailed look into cellular-based immunotherapies including CAR-T, TCR-T, TIL, Viral CTLs, NK cells in addition to T/NK cell engagers, focusing on their historical perspectives, biology, development and manufacturing, toxicities and more. Edited by two leading experts on gene and cellular immunotherapy, the book will feature chapters written by a diverse collection of recognized and up-and-coming experts and researchers in the field, providing oncologists, immunologists, researchers and clinical and basic science trainees with a bench to bedside view of the latest developments in the field. |
| car t vs tcr therapy: Oncoimmunology Laurence Zitvogel, Guido Kroemer, 2017-12-13 In this book, leading experts in cancer immunotherapy join forces to provide a comprehensive guide that sets out the main principles of oncoimmunology and examines the latest advances and their implications for clinical practice, focusing in particular on drugs with FDA/EMA approvals and breakthrough status. The aim is to deliver a landmark educational tool that will serve as the definitive reference for MD and PhD students while also meeting the needs of established researchers and healthcare professionals. Immunotherapy-based approaches are now inducing long-lasting clinical responses across multiple histological types of neoplasia, in previously difficult-to-treat metastatic cancers. The future challenges for oncologists are to understand and exploit the cellular and molecular components of complex immune networks, to optimize combinatorial regimens, to avoid immune-related side effects, and to plan immunomonitoring studies for biomarker discovery. The editors hope that this book will guide future and established health professionals toward the effective application of cancer immunology and immunotherapy and contribute significantly to further progress in the field. |
| car t vs tcr therapy: HIV-1 Latency Guido Silvestri, Mathias Lichterfeld, 2018-10-11 This volume summarizes recent advances in understanding the mechanisms of HIV-1 latency, in characterizing residual viral reservoirs, and in developing targeted interventions to reduce HIV-1 persistence during antiretroviral therapy. Specific chapters address the molecular mechanisms that govern and regulate HIV-1 transcription and latency; assays and technical approaches to quantify viral reservoirs in humans and animal models; the complex interchange between viral reservoirs and the host immune system; computational strategies to model viral reservoir dynamics; and the development of therapeutic approaches that target viral reservoir cells. With contributions from an interdisciplinary group of investigators that cover a broad spectrum of subjects, from molecular virology to proof-of-principle clinical trials, this book is a valuable resource for basic scientists, translational investigators, infectious-disease physicians, individuals living with HIV/AIDS and the general public. |
| car t vs tcr therapy: Haploidentical Transplantation Stefan O. Ciurea, Rupert Handgretinger, 2018-05-03 In this book, world-renowned experts in the field express well-reasoned opinions on a range of issues and controversies relating to haploidentical transplantation with the aim of providing practicing hematologists with clinically relevant and readily applicable information. Among the areas covered are graft manipulation and methods to control T-cell alloreactivity, the nature of the ideal graft and donor, haploidentical transplantation in pediatric and adult patients with malignant and nonmalignant diseases, immunologic reconstitution following transplantation, complications, and the prevention and treatment of relapse post transplantation. Attention is drawn to the implications of high-impact clinical trials whenever such trials are available. The readily intelligible text is complemented by numerous helpful tables, algorithms, and figures. The book will provide practical support for hematologists and transplant physicians as they attempt to provide optimal care in this exciting but increasingly complex medical specialty. |
| car t vs tcr therapy: Developing Costimulatory Molecules for Immunotherapy of Diseases Manzoor Ahmad Mir, 2015-05-25 Developing Costimulatory Molecules for Immunotherapy of Diseases highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy using either humanized antibodies against CD80, CD86, and other costimulatory molecules or CD28 fusinogenic proteins in the treatment of diseases, including allergies, asthma, rheumatoid arthritis, multiple sclerosis, lupus nephritis, severe psoriasis, vulgaris tuberculosis, thopoid, transplantation therapeutic, cancer, and inflammation. The text aims to provide the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families, with the hope that targeting these families will yield new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases. - Highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy - Provides the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families - Targets new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases |
| car t vs tcr therapy: Chimeric Antigen Receptor T Cells Kamilla Swiech, Kelen Cristina Ribeiro Malmegrim, Virgínia Picanço-Castro, 2020-11-24 This volume provides comprehensive methods from expert scientists working in the Chimeric Antigen Receptor T Cell (CAR-T Cell) field. Chapters guide readers through the state-of-art of CAR-T cell technology, CAR design and vector production, CAR-T cell generation and manufacturing, CAR-T cell characterization, and quality control. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and cutting-edge, Chimeric Antigen Receptor T Cells: Development and Production aims to be useful in the production of CAR-T cells, especially for therapeutic purposes. |
| car t vs tcr therapy: Cognitive Therapy for Depressed Adolescents , 1994-07-08 Applying Marlatt's elegant research on relapse prevention to problem drinking, smoking, substance abuse, eating disorders, and compulsive gambling, this volume analyzes factors that may lead to relapse and offers practical techniques for maintaining treatment gains. Featuring strategies derived from years of clinical work and repeated testing, this hands-on manual provides patient-therapist narratives that convey a clinical feel for how this therapy works, as well as actual case vignettes illustrating effective techniques for diagnosis and treatment. |
| car t vs tcr therapy: Cancer Immunology and Immunotherapy Mansoor M. Amiji, Lara Scheherazade Milane, 2021-08-18 Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncology therapies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. Nanotechnology-based targeted delivery strategies could improve the delivery efficiency of IO agents as well as provide additional avenues for novel therapeutic and vaccination strategies. Additionally, a number of locally-administered immunogenic scaffolds and therapeutic strategies, such as the use of STING agonist, could benefit from rationally designed biomaterials and delivery approaches. Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side. - Comprehensive treaty covering all aspects of immuno-oncology (IO) - Novel strategies for delivery of IO therapeutics and vaccines - Forecasting on the future of nanotechnology and drug delivery for IO |
| car t vs tcr therapy: Protein Engineering Huimin Zhao, 2021-08-23 A one-stop reference that reviews protein design strategies to applications in industrial and medical biotechnology Protein Engineering: Tools and Applications is a comprehensive resource that offers a systematic and comprehensive review of the most recent advances in the field, and contains detailed information on the methodologies and strategies behind these approaches. The authors—noted experts on the topic—explore the distinctive advantages and disadvantages of the presented methodologies and strategies in a targeted and focused manner that allows for the adaptation and implementation of the strategies for new applications. The book contains information on the directed evolution, rational design, and semi-rational design of proteins and offers a review of the most recent applications in industrial and medical biotechnology. This important book: Covers technologies and methodologies used in protein engineering Includes the strategies behind the approaches, designed to help with the adaptation and implementation of these strategies for new applications Offers a comprehensive and thorough treatment of protein engineering from primary strategies to applications in industrial and medical biotechnology Presents cutting edge advances in the continuously evolving field of protein engineering Written for students and professionals of bioengineering, biotechnology, biochemistry, Protein Engineering: Tools and Applications offers an essential resource to the design strategies in protein engineering and reviews recent applications. |
| car t vs tcr therapy: Self and Nonself Carlos López-Larrea, 2012-03-07 In 1960 Sir Frank Macfarlane Burnet received the Noble Prize in Physiology and Medicine. He titled his Nobel Lecture “Immunological Recognition of Self” emphasizing the central argument of immunological tolerance in “How does the vertebrate organism recognize self from nonself in this the immunological sense—and how did the capacity evolve.” The concept of self is linked to the concept of biological self identity. All organisms, from bacteria to higher animals, possess recognition systems to defend themselves from nonself. Even in the context of the limited number of metazoan phyla that have been studied in detail, we can now describe many of the alternative mechanism of immune recognition that have emerged at varying points in phylogeny. Two different arms—the innate and adaptive immune system—have emerged at different moments in evolution, and they are conceptually different. The ultimate goals of immune biology include reconstructing the molecular networks underlying immune processes. |
| car t vs tcr therapy: Co-signal Molecules in T Cell Activation Miyuki Azuma, Hideo Yagita, 2019-11-22 This book equips young immunologists and health professionals with a clear understanding of the fundamental concepts and roles of co-signal molecules and in addition presents the latest information on co-stimulation. The first part of the book is devoted to co-signal molecules and the regulation of T cells. Following an initial overview, subsequent chapters examine each co-signal molecule in turn and discuss the mechanisms by which co-signal molecules regulate the different types of T cell. The second part covers various clinical applications, including in autoimmune disease, neurological disorders, transplantation, graft-versus-host disease, and cancer immunotherapy. To date, co-stimulation blockade and co-inhibition blockade have shown beneficial effects and many additional clinical trials targeting co-signal molecules are ongoing. The mechanisms underlying these successful treatments are explained and the future therapeutic potential in the aforementioned diseases is evaluated. Co-signal Molecules in T Cell Activation will be a valuable reference guide to co-stimulation for basic and clinical researchers in the fields of both immunology and pharmaceutical science. |
| car t vs tcr therapy: Brain Tumor Imaging Elke Hattingen, Ulrich Pilatus, 2015-09-02 This book describes the basics, the challenges and the limitations of state of the art brain tumor imaging and examines in detail its impact on diagnosis and treatment monitoring. It opens with an introduction to the clinically relevant physical principles of brain imaging. Since MR methodology plays a crucial role in brain imaging, the fundamental aspects of MR spectroscopy, MR perfusion and diffusion-weighted MR methods are described, focusing on the specific demands of brain tumor imaging. The potential and the limits of new imaging methodology are carefully addressed and compared to conventional MR imaging. In the main part of the book, the most important imaging criteria for the differential diagnosis of solid and necrotic brain tumors are delineated and illustrated in examples. A closing section is devoted to the use of MR methods for the monitoring of brain tumor therapy. The book is intended for radiologists, neurologists, neurosurgeons, oncologists and other scientists in the biomedical field with an interest in neuro-oncology. |
| car t vs tcr therapy: Immunopharmacogenomics Yusuke Nakamura, 2015-09-18 This book proposes immunogenomics, or immunopharmacogenomics, as the next-generation big science to uncover the role that the immune system plays in the pathogenesis of many diseases, by summarizing the importance of the deep sequencing of T-cell and B-cell receptors. Immunogenomics/immunopharmacogenomics, a genetic characterization of the immune system made possible by next-generation sequencing (NGS), will be important for the further understanding of the pathogenesis of various disease conditions. Abnormal immune responses in the body lead to development of autoimmune diseases and food allergies. Rejection of recipient cells and tissues, as well as severe immune reactions to donor cells, is also the result of uncontrolled immune responses in the recipient body. There have been many reports indicating that activated immune responses caused by the interaction of drugs and HLA are present in drug-induced skin hypersensitivity and liver toxicity. The importance of the host immune responses has been recognized in cancer treatments, not only for immunotherapy but also for cytotoxic agents and molecular targeted drugs. Hence, characterization of the T-cell receptor and B-cell receptor repertoire by means of NGS deep sequencing will ultimately make possible the identification of the molecular mechanisms that underlie various diseases and drug responses. In addition, this approach may contribute to the identification of antigens associated with the onset or progression of autoimmune diseases as well as food allergies. Although the germline alterations and somatic mutations have been extensively analyzed, changes or alterations of the immune responses during the course of various disease conditions or during various treatments have not been analyzed. It is also clear that computational analyses to draw meaningful inferences of functional recognition receptors on the immune cells remain a huge challenge. |
| car t vs tcr therapy: Adoptive Immunotherapy Burkhard Ludewig, Matthias W. Hoffmann, 2008-02-02 An authoritative collection of optimal techniques for producing and characterizing the immunologically active cells and effector molecules now gaining wide use in the clinical treatment of patients. Taking advantage of the latest technologies, the authors present readily reproducible experimental protocols for the study of dendritic cells, T cells, monoclonal antibodies, and bone marrow transplantation. The emphasis is on preclinicical and clinical applications and on the progress of selected approaches in clinical trials. Additional chapters cover the molecular definition of target antigens, mathematical modeling approaches to immunotherapy, and the utilization of regulatory T cells. The protocols make it possible to study the adoptive transfer of tailored antigen-specific immune cells and to improve the clinical application of adoptive immunotherapy. |
| car t vs tcr therapy: Heparanase Israel Vlodavsky, Ralph D. Sanderson, Neta Ilan, 2020-04-09 Written by internationally recognized leaders in Heparanase biology, the book’s eight chapters offer an opportunity for scientists, clinicians and advanced students in cell biology, tumor biology and oncology to obtain a comprehensive understanding of Heparanase’s multifaceted activities in cancer, inflammation, diabetes and other diseases, as well as its related clinical applications. Proteases and their involvement in cancer progression have been well addressed and documented; however, the emerging premise presented within this book is that Heparanase is a master regulator of aggressive cancer phenotypes and crosstalk with the tumor microenvironment. This endoglycosidase contributes to tumor-mediated remodeling of the extracellular matrix and cell surfaces, augmenting the bioavailability of pro-tumorigenic and pro-inflammatory growth factors and cytokines that are bound to Heparan sulfate. Compelling evidence ties Heparanase with all steps of tumor progression including tumor initiation, growth, angiogenesis, metastasis, and chemoresistance, supporting the notion that Heparanase is an important contributor to the poor outcome of cancer patients and a validated target for therapy. Unlike Heparanase, heparanase-2, a close homolog of Heparanase, lacks enzymatic activity, inhibits Heparanase, and regulates selected genes that promote normal differentiation and tumor suppression. Written by internationally recognized leaders in Heparanase biology, this volume presents a comprehensive understanding of Heparanase’s multifaceted activities in cancer, inflammation, diabetes and other diseases, as well as its related clinical applications to scientists, clinicians and advanced students in cell biology, tumor biology and oncology. |
| car t vs tcr therapy: Cancer Vaccines and Immunotherapy Peter L. Stern, Peter C. L. Beverley, Miles Carroll, 2000-08-17 Rapid progress in the definition of tumor antigens, and improved immunization methods, bring effective cancer vaccines within reach. In this wide-ranging survey, leading clinicians and scientists review therapeutic cancer vaccine strategies against a variety of diseases and molecular targets. Intended for an interdisciplinary readership, their contributions cover the rationale, development, and implementation of vaccines in human cancer treatment, with specific reference to cancer of the cervix, breast, colon, bladder, and prostate, and to melanoma and lymphoma. They review target identification, delivery vectors and clinical trial design. The book begins and ends with lucid overviews from the editors, that discuss the most recent developments. |
| car t vs tcr therapy: Immunotherapy of Hepatocellular Carcinoma Tim F. Greten, 2018-08-22 In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients. |
| car t vs tcr therapy: Advances in Precision Medicine Oncology Hilal Arnouk, Bassam Abdul Rasool Hassan, 2021 Recent advances in precision medicine and immuno-oncology have led to highly specific and efficacious cancer therapies such as monoclonal antibodies and immune checkpoint inhibitors (ICIs). This book provides an up-to-date overview of advances in the field of immuno-oncology. Chapters cover such topics as ICIs and how they mount a robust immune response against cancer cells as well as the response of ICIs to treatment predictive biomarkers and their potential immune-related adverse events (irAEs). Additionally, the book includes a comprehensive review of the powerful FDA-approved therapeutic agent doxorubicin, highlighting the molecular mechanisms behind doxorubicin's drug resistance and critical side effects. |
| car t vs tcr therapy: Cutaneous T-Cell Lymphoma Herschel S. Zackheim, 2004-10-28 Cutaneous T-cell lymphoma (CTCL) is a general term for many lymphomas of the skin including mycosis Fungoides and Sezary syndrome. This book presents the state of the art in CTCL epidemiology, clinical features, pathology, immunochemistry, diagnostic molecular techniques, staging and prognosis, and treatment. Edited by one of the leading experts in |
| car t vs tcr therapy: Therapeutic Antibodies Yuti Chernajovsky, Ahuva Nissim, 2007-11-22 This essential work, edited by two researchers at London’s famous Queen Mary’s medical school targets one of the most important areas in medical development today. These days, antibody therapeutics are the treatment of choice for several autoimmune and oncological conditions. They are, indeed, becoming the molecules of choice for further combination therapies and cell engineering. In this timely work, a slew of expert in the field of drug development summarize all the current developments and clinical successes. |
| car t vs tcr therapy: Treatment of Leukemia and Lymphoma David A. Scheinberg, Joseph G. Jurcic, 2004-10-30 New Treatments of Leukemia and Lymphoma describes the most important advances in the therapy of hematopoietic cancers that have been derived from recent discoveries in cancer cell biology, kinase biochemistry, and immunology. Detailed descriptions of the large number of new and effective agents that have recently become available for the treatment of leukemias and lymphomas as well as an understanding of their mechanisms of action and their integration into current therapy are provided. A number of experimental drug reagents currently in clinical investigation are also discussed. The therapies include conventional anti-metabolites, monoclonal antibodies directed to cell surface receptors, antibodies tagged with toxins and radiopharmaceuticals, inhibitors of specific kinases, stem cell transplants, and engineered T-cells designed to selectively target hematopoietic cancers. The contents of the book will allow practitioners and investigators alike to understand what is current and state of the art as well as what to look for in the future.* Provides an up-to-date, state of the art discussion of a rapidly changing field * Great breadth covering conventional chemotherapeutic agents, biologic agents such as antibodies, novel small molecule inhibitors and genetically engineered cells * Written by international experts in each of the fields |
| car t vs tcr therapy: Pediatric Neuro-oncology Katrin Scheinemann, Eric Bouffet, 2015-03-26 “The editors...have done an outstanding job of presenting...complex information in a lucid manner – this book is a must-read for the global community of aspiring students and neuro-oncology practitioners.” Amar Gajjar, MD in the Foreword This is a succinct introduction to pediatric neuro-oncology. It summarizes the key advances in molecular biology that have helped transform this rapidly evolving field and provides up-to-date coverage of major and emerging treatment modalities as well as supportive care. Separate chapters present each kind of pediatric brain cancer and its diagnosis and treatment. As more children survive brain cancer, the importance of quality of life issues and helping survivors to cope with the neuropsychological impact and long-term effects of current therapies has come into sharper focus; these topics are also addressed in the book, as are palliative care and pediatric neuro-oncology in countries with limited resources. The book is aimed at trainees and practitioners who seek an up-to-date text in pediatric neuro-oncology that is both comprehensive and concise. |
| car t vs tcr therapy: The Immune Response Tak W. Mak, Mary E. Saunders, 2005-11-11 The Immune Response is a unique reference work covering the basic and clinical principles of immunology in a modern and comprehensive fashion. Written in an engaging conversational style, the book conveys the broad scope and fascinating appeal of immunology. The book is beautifully illustrated with superb figures as well as many full color plates. This extraordinary work will be an invaluable resource for lecturers and graduate students in immunology, as well as a vital reference for research scientists and clinicians studying related areas in the life and medical sciences. - Current and thorough 30 chapter reference reviewed by luminaries in the field - Unique 'single voice' ensures consistency of definitions and concepts - Comprehensive and elegant illustrations bring key concepts to life - Provides historical context to allow fuller understanding of key issues - Introductory chapters 1-4 serve as an 'Immunology Primer' before topics are discussed in more detail |
| car t vs tcr therapy: Basics of Chimeric Antigen Receptor (CAR) Immunotherapy Mumtaz Y. Balkhi, 2019-07-31 Basics of Chimeric Antigen Receptor (CAR) Immunotherapy presents the latest on how T cell adoptive immunotherapy has progressed in its ultimate goal of curing metastatic malignant cancers. Recent clinical data obtained with checkpoint receptor blockade inhibitors and chimeric antigen receptor (CAR) therapy has been especially promising, thus generating renewed hope that we may be on the verge of finally curing cancer. Over the years, huge progress has been made in controlling several stage IV metastasized cancers through the clinical application of checkpoint receptor inhibitory drugs and CAR-Therapy that has seen unprecedented interest in the immunotherapy field. - Presents the first book to provide a basic understanding of chimeric antigen receptor (CARs) design, production and clinical application protocols - Provides unique authority as the editor has worked directly with CARs - Discusses the challenges encountered in actual clinical trials and how these challenges can be overcome - Includes a full chapter on various challenges researchers should expect to encounter in the CAR-therapy field |
| car t vs tcr therapy: DNA Methylation and Complex Human Disease Michel Neidhart, 2015-08-11 DNA Methylation and Complex Human Disease reviews the possibilities of methyl-group-based epigenetic biomarkers of major diseases, tailored epigenetic therapies, and the future uses of high-throughput methylome technologies. This volume includes many pertinent advances in disease-bearing research, including obesity, type II diabetes, schizophrenia, and autoimmunity. DNA methylation is also discussed as a plasma and serum test for non-invasive screening, diagnostic and prognostic tests, as compared to biopsy-driven gene expression analysis, factors which have led to the use of DNA methylation as a potential tool for determining cancer risk, and diagnosis between benign and malignant disease. Therapies are at the heart of this volume and the possibilities of DNA demethylation. In cancer, unlike genetic mutations, DNA methylation and histone modifications are reversible and thus have shown great potential in the race for effective treatments. In addition, the authors present the importance of high-throughput methylome analysis, not only in cancer, but also in non-neoplastic diseases such as rheumatoid arthritis. - Discusses breaking biomarker research in major disease families of current health concern and research interest, including obesity, type II diabetes, schizophrenia, and autoimmunity - Summarizes advances not only relevant to cancer, but also in non-neoplastic disease, currently an emerging field - Describes wholly new concepts, including the linking of metabolic pathways with epigenetics - Provides translational researchers with the knowledge of both basic research and clinic applications of DNA methylation in human diseases |
| car t vs tcr therapy: Immune Regulation Marc Feldmann, N. A. Mitchison, 2012-12-06 Leukocyte culture conferences have a long pedigree. This volume records some of the scientific highlights of the 16th such annual con ference, and is a witness to the continuing evolution and popularity of leukocyte culture and of immunology. There is strong evidence of the widening horizons of immunology, both technically, with the obviously major impact of molecular biology into our understanding of cellular processes, and also conceptually. Traditionally, the 'proceedings' of these conferences have been published. But have the books produced really recorded the major part of the conference, the informal, friendly, but intense and some times heated exchanges that take place between workers in tackling very similar problems and systems and which are at the heart of every successful conference? Unfortunately this essence cannot be incorpo rated by soliciting manuscripts. For this reason, we have changed the format of publication, retaining published versions of the symposium papers, but requesting the workshop chairmen to produce a summary of the major new observations and areas of controversy highlighted in their sessions, as a vehicle for defining current areas of interest and debate. Not an easy task, as the workshop topics were culled from the abstracts submitted by the participants, rather than being on predefined topics. The unseasonal warmth in Cambridge was reflected in the atmos phere of the conference, the organization of which benefited from the administrative skills of Jean Bacon, Philippa Wells, Mr. Peter Irving, and Mrs. |
| car t vs tcr therapy: Bioreactor Systems for Tissue Engineering Cornelia Kasper, Martijn van Griensven, Ralf Pörtner, 2009-02-03 The editors of this special volume would first like to thank all authors for their excellent contributions. We would also like to thank Prof. Dr. Thomas Scheper, Dr. Marion Hertel and Ulrike Kreusel for providing the opportunity to compose this volume and Springer for organizational and technical support. Tissue engineering represents one of the major emerging fields in modern b- technology; it combines different subjects ranging from biological and material sciences to engineering and clinical disciplines. The aim of tissue engineering is the development of therapeutic approaches to substitute diseased organs or tissues or improve their function. Therefore, three dimensional biocompatible materials are seeded with cells and cultivated in suitable systems to generate functional tissues. Many different aspects play a role in the formation of 3D tissue structures. In the first place the source of the used cells is of the utmost importance. To prevent tissue rejection or immune response, preferentially autologous cells are now used. In particular, stem cells from different sources are gaining exceptional importance as they can be differentiated into different tissues by using special media and supplements. In the field of biomaterials, numerous scaffold materials already exist but new composites are also being developed based on polymeric, natural or xenogenic sources. Moreover, a very important issue in tissue en- neering is the formation of tissues under well defined, controlled and reprod- ible conditions. Therefore, a substantial number of new bioreactors have been developed. |
| car t vs tcr therapy: Brain Tumor Immunotherapy Linda M. Liau, Donald P. Becker, Timothy F. Cloughesy, Darell D. Bigner, 2000-11-10 An authoritative panel of researchers and clinicians critically reviews the entire field to provide a comprehensive guide to modern brain tumor immunotherapy and thereby enhance future research in this area. The contributors detail many of the key laboratory experiments and clinical protocols that are currently being investigated, integrate the available information from previous and ongoing research, and help define the current status of the field. Topics range from adoptive cellular and antibody-mediated immunotherapy of brain tumors to tumor vaccines and related strategies, and include many vanguard experimental strategies and immunological techniques for studying brain tumor immunotherapy. Cutting-edge and comprehensive, Brain Tumor Immunotherapy brings together all the important recent advances in our understanding of central nervous system tumor immunology and illustrates in powerful detail the many new applications now harnessing the immune response for brain tumor therapeutics. |
| car t vs tcr therapy: Drug Resistance in Leukemia & Gert-Jan L. Kaspers, 1993-01-01 The last ten years have seen the publication of a vast amount of data regarding cellular resistance to drugs in cancer cells. Recent studies have demonstrated that drug resistance assays appear to be predictive of clinical response and suggest that clinicians should now be considering the potential applications of these assays in the treatment of patients with hematological neoplasms. This collection of papers from the International Symposium on the Clinical Value of Drug Resistance Assays in Leukemia and Lymphoma, Amsterdam, 1992, provides a state-of-the-art discussion on drug resistance assays and their role in the design and individualization of treatment protocols. |
| car t vs tcr therapy: Handbook of Vertebrate Immunology Paul-Pierre Pastoret, 1998-06-02 This unique book provides a comprehensive and comparative guide to the immune systems of major vertebrate species, including domestic and wild animals of veterinary or medical interest, fish and amphibia. Data in this essential reference work has been compiled by world-renowned editors and an international group of authors. For each species, the information is presented in a structured 'user-friendly' format allowing easy cross reference and comparison between the various species. This book will be considered the definitive reference work on vertebrate immunology and will be essential for scientists and professionals working in Immunology, Vaccinology or with Animal Models, for students of Veterinary or Human Medicine, Biology and researchers in Comparative Medicine and Physiology. Each section, devoted to a major animal group covers: Lymphoid organs and their anatomical disposition Leukocytes and their markers Leukocyte traffic and associated molecules Cytokines T cell receptors Immunoglobulins MHC antigens Ontogeny of the immune system Passive transfer of immunity Neonatal immune responses Non-specific immunity Complement system Mucosal immunity Immunodeficiencies Tumours of the immune system Autoimmunity |
| car t vs tcr therapy: Successful Drug Discovery, Volume 5 Janos Fischer, Christian Klein, Wayne E. Childers, 2021-02-12 Filled with unique insights into current drugs that have made it to the marketplace In the fifth volume of Successful Drug Discovery, the inventors and primary developers of drugs that made it to the market tell the story of the drugs discovery and development. Case studies of drugs from different therapeutic fields reveal the all-too-often unpredictable path from the first drug candidate molecule to the successfully marketed drug. In addition, this new volume addresses overarching topics for drug discovery, such as drug discovery in academia, and discusses currently important classes of small molecule as well as biological drugs. Comprehensive in scope, the books nine chapters provide a representative cross-section of the present-day drug development effort. The authoritative fifth volume is filled with relevant data and chemical information, as well as the insight and experience of the best contemporary drug creators. This important volume: - Puts the focus on recently introduced drugs that have not yet made it into standard textbooks or general references - Contains information and insight that is new and often not even available from the primary literature - Reveals what it takes to successfully develop a drug molecule that has made it all the way to the market - Is endorsed and supported by the International Union of Pure and Applied Chemistry (IUPAC) Written for medicinal chemists, pharmaceutical chemists, organic chemists, Successful Drug Discovery, Volume Five reveals the most recent techniques used by drug innovators in the drug development process. |
| car t vs tcr therapy: Guidelines for Preparing Patent Landscape Reports World Intellectual Property Organization, 2015-08-24 These Guidelines are designed both for general users of patent information, as well as for those involved in producing Patent Landscape Reports (PLRs). They provide step-by-step instructions on how to prepare a PLR, as well as background information such as objectives, patent analytics, concepts and frameworks. |
| car t vs tcr therapy: Cancer Patient Survival National Cancer Institute (U.S.), 1976 |
| car t vs tcr therapy: Ovarian Cancer Immunotherapy Samir A. Farghaly, 2018-08-31 Ovarian Cancer Immunotherapy provides a broad overview of several aspects of basic sciences, and clinical and therapeutic aspects of immunotherapy for ovarian cancer, as well as state-of-the-art information on molecular genetics and biology. Chapters are written by a team of expert contributors from around the world and explore topics such as antibody therapeutics for ovarian carcinoma, emerging serum biomarkers, ovarian cancer immunity, adoptive cell immunotherapy, the biology of dendritic cells, the role of growth factors, and more. Readers will also gain a better understanding of the molecular and cellular events that underlie ovarian cancer immunology. This book is an ideal resource for clinicians, basic medical scientists, graduate basic medical science students, and medical students caring for patients with ovarian cancer, including attending surgeons and physicians, and clinical fellows and residents in the disciplines of gynecologic oncology, medical oncology, and surgical oncology. |
| car t vs tcr therapy: Natural Killer Cells Srinivas S. Somanchi, 2016-05-13 This volume contains collection of Natural Killer Cell methodologies relevant for both basic and translational research. These methodologies present new developments in the natural killer (NK) cell field, such as understanding the influence of NK cells metabolism on its function, identifying complexity of NK cell subsets through mass cytometry, and determining the emergence of memory NK cells in murine model of MCMV infection. Methods that study NK cell migration and cytotoxicity through endpoint analysis or live single cell imaging are also discussed. Chapters also describe methods pertaining to translational application of NK cells, such as ex vivo expansion of NK cells on K562 cell lines genetically modified to express either membrane bound IL-15 or membrane bound IL-21, large scale NK cell culture, current techniques for engineering NK cells to express chimeric antigen receptors or chemokine receptors using retroviral vectors, electroporation of mRNA, and the natural phenomenon of trogocytosis. Written in the highly successful Methods in Molecular Biology series format, these chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Cutting edge and thorough, Natural Killer Cells: Methods and Protocols is a valuable resource for researchers who not only want to understand mechanisms that govern NK cell behavior and diversity, but also for those who want to understand how to systematically evaluate NK cells for adoptive immunotherapy applications. |
| car t vs tcr therapy: Lymphocyte Activation L.E. Samelson, H. Renz, 1994 |
| car t vs tcr therapy: Cancer Immunotherapy Principles and Practice Lisa H. Butterfield, Howard L. Kaufman, Francesco M. Marincola, 2017 Part 1: Intratumoral Signatures Associated With Immune Responsiveness |
Who wins the combat, CAR or TCR? - Nature
Chimeric antigen receptor T (CAR-T) cell therapy has drawn increasing attention over the last few decades given its remarkable effectiveness and breakthroughs in treating B cell...
CAR T-Cell Therapy Development: Guidance - Adaptive Biotech
antigen receptor (CAR) T-cell therapies. This guidance includes specific recommendations for the various phases of CAR T-cell development, as well as sequencing at different stages of …
Considerations for the Development of Chimeric Antigen …
In this guidance, we, FDA, provide CAR T cell-specific recommendations regarding chemistry, manufacturing, and control (CMC), pharmacology and toxicology, and design of clinical studies …
UNDERSTANDING CAR-T VS TCR APPROACHES - The Scientist
Engineered CAR T cells expressing therapeutic payloads can transform the immunosuppressive environment of solid tumors, such as through producing and secreting proinflammatory cytokines.
Chimeric Antigen Receptor T Cell Therapy - Cancer and …
May 13, 2016 · TCR CD3ζ T Cell Receptor Chimeric Antigen Receptor CAR T cells are genetically altered to express CAR on the cell surface. CAR Design: Critical Elements of T Cell …
Chimeric Antigen Receptor T-Cell Therapy Current Perspective …
Here, we review the core structure of the CAR, the evolution of different CAR generations, CAR T-cell therapy limitations, and current strategies being investigated to over-come the T …
Creating the Shift from Autologous to Allogeneic CAR T Therapy
• Risk of GvHD can be reduced by inactivating T cell receptors (TCR) • Mild cases of Grade 1 acute GvHD reactions limited to skin observed with UCART19 in ongoing clinical studies(ASH …
CAR-T Therapy for Blood Cancers - Maryland Department of …
Advantages of CAR-T Immunotherapy Kills “resistant” tumors (e.g. 17p – P53 del) Penetrates “sanctuary” sites (e.g. CNS) Through expansion and serial killing can eradicate “large” tumors …
Facts About Chimeric Antigen Receptor (CAR) T-Cell Therapy
will explain the rationale behind CAR T-cell therapy, describe approved therapies, summarize efficacy results to date, detail significant risks that have emerged, provide practical medical …
Car T Vs Tcr Therapy (Download Only) - old.icapgen.org
patient referral to post therapy management Chimeric Antigen Receptor CAR T Cell Therapies for Cancer A Practical Guide presents a comprehensive view of CAR modified T cells in a concise …
T CELL THERAPY AND CARTOX MANAGEMENT FOR NURSES
What is CAR T cell? Why CAR T cells? What does normal T cells do? HOW DO WE TREAT CRS? Tocilizumab is a part of the admission order set in supportive treatment plan. The …
Landscape of cancer cell therapies: trends and real-world data …
Since tisagenlecleucel (Kymriah) was approved by the FDA in 2017, five more chimeric antigen receptor (CAR)-T cell therapies have gained approval, the last one of which, ciltacabtagene...
Presentation Slides CAR T-Cell - Leukemia & Lymphoma Society
What is CAR T-cell therapy? CAR T-cell therapy is a type of cancer therapy that uses a patient’s own modified white blood cells to kill cancer cells. The emergence of CAR-T therapy, like most …
NFAT and NF-κB dynamically co-regulate TCR and CAR …
Pathway integration is further regulated temporally, where T cell receptor (TCR) and chimeric antigen recep-tor (CAR) activation signals modulate the temporal relationships between the …
Chimeric Antigen Receptor T-Cell Therapy Clinical Guideline
Chimeric antigen receptor (CAR) T-cell therapy is an adoptive T-cell therapy that uses engineered T cells from a patient’s own immune system to attack cancer cells by targeting proteins …
CAR T cell therapy vs. CAR NK cell therapy - Celyad
Here we describe the differences between CAR T cell therapies and CAR NK cell therapies to consider when developing cancer treatments for patients. T cells are part of the adaptive …
Joining Forces for Cancer Treatment: From TCR versus CAR to …
Herein, we provide a comprehensive review about similarities and differences by directly comparing the architecture, synapse formation and signaling of TCRs and CARs, highlighting …
Car T Vs Tcr Therapy Full PDF - old.icapgen.org
patient referral to post therapy management Chimeric Antigen Receptor CAR T Cell Therapies for Cancer A Practical Guide presents a comprehensive view of CAR modified T cells in a concise …
Facts About Chimeric Antigen Receptor (CAR) T-Cell Therapy
CAR T-cell therapy equips a patient’s T cells with the ability to detect and destroy malignant cells by combining the specificity of a monoclonal antibody with the cytotoxic and memory …
Chimeric Antigen Receptor T-cell (CAR-T) therapy
CAR-T is different from most other cancer treatments because it is made from your own white blood cells (T cells), which have been ‘reprogrammed’ in the laboratory to be able to target …
Who wins the combat, CAR or TCR? - Nature
Chimeric antigen receptor T (CAR-T) cell therapy has drawn increasing attention over the last few decades given its remarkable effectiveness and breakthroughs in treating B cell...
CAR T-Cell Therapy Development: Guidance - Adaptive Biotech
antigen receptor (CAR) T-cell therapies. This guidance includes specific recommendations for the various phases of CAR T-cell development, as well as sequencing at different stages of …
Considerations for the Development of Chimeric Antigen …
In this guidance, we, FDA, provide CAR T cell-specific recommendations regarding chemistry, manufacturing, and control (CMC), pharmacology and toxicology, and design of clinical studies …
UNDERSTANDING CAR-T VS TCR APPROACHES - The Scientist
Engineered CAR T cells expressing therapeutic payloads can transform the immunosuppressive environment of solid tumors, such as through producing and secreting proinflammatory cytokines.
Chimeric Antigen Receptor T Cell Therapy - Cancer and …
May 13, 2016 · TCR CD3ζ T Cell Receptor Chimeric Antigen Receptor CAR T cells are genetically altered to express CAR on the cell surface. CAR Design: Critical Elements of T Cell …
Chimeric Antigen Receptor T-Cell Therapy Current …
Here, we review the core structure of the CAR, the evolution of different CAR generations, CAR T-cell therapy limitations, and current strategies being investigated to over-come the T …
Creating the Shift from Autologous to Allogeneic CAR T …
• Risk of GvHD can be reduced by inactivating T cell receptors (TCR) • Mild cases of Grade 1 acute GvHD reactions limited to skin observed with UCART19 in ongoing clinical studies(ASH …
CAR-T Therapy for Blood Cancers - Maryland Department of …
Advantages of CAR-T Immunotherapy Kills “resistant” tumors (e.g. 17p – P53 del) Penetrates “sanctuary” sites (e.g. CNS) Through expansion and serial killing can eradicate “large” tumors …
Facts About Chimeric Antigen Receptor (CAR) T-Cell Therapy
will explain the rationale behind CAR T-cell therapy, describe approved therapies, summarize efficacy results to date, detail significant risks that have emerged, provide practical medical …
Car T Vs Tcr Therapy (Download Only) - old.icapgen.org
patient referral to post therapy management Chimeric Antigen Receptor CAR T Cell Therapies for Cancer A Practical Guide presents a comprehensive view of CAR modified T cells in a concise …
T CELL THERAPY AND CARTOX MANAGEMENT FOR NURSES
What is CAR T cell? Why CAR T cells? What does normal T cells do? HOW DO WE TREAT CRS? Tocilizumab is a part of the admission order set in supportive treatment plan. The …
Landscape of cancer cell therapies: trends and real-world data …
Since tisagenlecleucel (Kymriah) was approved by the FDA in 2017, five more chimeric antigen receptor (CAR)-T cell therapies have gained approval, the last one of which, ciltacabtagene...
Presentation Slides CAR T-Cell - Leukemia & Lymphoma …
What is CAR T-cell therapy? CAR T-cell therapy is a type of cancer therapy that uses a patient’s own modified white blood cells to kill cancer cells. The emergence of CAR-T therapy, like most …
NFAT and NF-κB dynamically co-regulate TCR and CAR …
Pathway integration is further regulated temporally, where T cell receptor (TCR) and chimeric antigen recep-tor (CAR) activation signals modulate the temporal relationships between the …
Chimeric Antigen Receptor T-Cell Therapy Clinical Guideline
Chimeric antigen receptor (CAR) T-cell therapy is an adoptive T-cell therapy that uses engineered T cells from a patient’s own immune system to attack cancer cells by targeting proteins …
CAR T cell therapy vs. CAR NK cell therapy - Celyad
Here we describe the differences between CAR T cell therapies and CAR NK cell therapies to consider when developing cancer treatments for patients. T cells are part of the adaptive …
Joining Forces for Cancer Treatment: From TCR versus CAR to …
Herein, we provide a comprehensive review about similarities and differences by directly comparing the architecture, synapse formation and signaling of TCRs and CARs, highlighting …
Car T Vs Tcr Therapy Full PDF - old.icapgen.org
patient referral to post therapy management Chimeric Antigen Receptor CAR T Cell Therapies for Cancer A Practical Guide presents a comprehensive view of CAR modified T cells in a concise …
Facts About Chimeric Antigen Receptor (CAR) T-Cell Therapy
CAR T-cell therapy equips a patient’s T cells with the ability to detect and destroy malignant cells by combining the specificity of a monoclonal antibody with the cytotoxic and memory …
Chimeric Antigen Receptor T-cell (CAR-T) therapy
CAR-T is different from most other cancer treatments because it is made from your own white blood cells (T cells), which have been ‘reprogrammed’ in the laboratory to be able to target …
